Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Makes US Acquisition

publication date: Jan 3, 2008

WuXi PharmaTech will pay $151 million to acquire privately held AppTec Laboratory Services of St. Paul, Minn. Like WuXi, AppTec is involved in contract research outsourcing. But, while WuXi concentrates on pre-clinical chemistry services, AppTech provides testing, biologics cGMP manufacturing and contract R&D to the biopharma and medical device sectors.  In 2007, AppTec produced just over $70 million of revenue, representing a compounded growth rate of 46% over the past three years. WuXi predicts its 2007 revenues will approach $135 million. More details... 

Stock Symbols: (NYSE: WX) (NYSE: DNA) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here